

Big Pharma: Gaming the system
10 snips Apr 16, 2025
Nick Dearden, author of PharmaNomics, and Phil Whitaker, a seasoned NHS GP, dive into the murky waters of Big Pharma's influence on healthcare. They discuss how pharmaceutical companies have historically manipulated doctors and the regulatory environment to prioritize profits. The dark legacy of OxyContin marketing reveals the dangerous consequences of profit-driven strategies. Dearden and Whitaker also advocate for rethinking pharmaceutical regulations, emphasizing the need for public interest over corporate profit, inspired by innovative models from countries like South Africa.
AI Snips
Chapters
Books
Transcript
Episode notes
Pharma Lavish Perks Anecdote
- Early pharmaceutical reps used lavish perks like hot air balloon rides and skiing resorts to influence UK doctors.
- Regulations in 2012 curbed these practices, shifting pharma focus towards institutional bodies like NICE.
Caution Needed With New Drugs
- New drugs often reveal serious side effects only after widespread use beyond initial trials.
- Doctors learn to be cautious 'late adopters' to avoid early harms from hyped medications.
NICE Approval and Pricing Insight
- NICE approval ensures health system-wide drug access but may push risky early adoption.
- Cost per quality-adjusted life year (QALY) guides drug pricing and approval decisions.